A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants with MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Participation Requirements

• Sex:

  ALL

• Eligible Ages:

  18 to 75

Participation Criteria

Key Inclusion Criteria:

* Males or non-pregnant females aged between 18 and 75 years (inclusive) at time of signing the informed consent form (ICF)
* Biopsy-confirmed MASH (previously named NASH) with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation (qualifying biopsy must be either within 6 months of screening visit \[with additional requirements\] or obtained during screening period)
* Body mass index (BMI) at screening ≥25.0 (≥23 for Asian participants) and \<50.0 kilograms (kg)/meters squared (m\^2)

Key Exclusion Criteria:

* Chronic liver diseases other than MASH/NASH
* History or evidence of cirrhosis on screening liver biopsy
* Have type 1 diabetes or poorly controlled type 2 diabetes
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥250 units per liter (U/L)
* Participants taking vitamin E (\>400 international units \[IU\]/day) must be on stable dose for at least 6 months prior to screening

Other inclusion and exclusion criteria may apply.